Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2021-10-05 00:00:00 ET · period of report 2021-10-01 · accession 0001567619-21-017895 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-10-05 | 2021-10-01 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | S - Sale+OE | $25.01 | -1,500 | 594.8K | -0.3% | -$37.5K |
| D | 2021-10-05 | 2021-10-01 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | M - OptEx | $1.68 | +1,500 | 596.3K | +0.3% | +$2,520 |
| D | 2021-10-05 | 2021-10-01 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | M - OptEx | $0.00 | -1,500 | 126.1K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-01 | S | D | 1,500 | $25.01 | 594,779 | D | — | — | (F3) The transaction was executed in multiple trades in prices ranging from $25.00 to $25.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. |
| 2 | Common | Common Stock | 2021-10-01 | M | A | 1,500 | $1.68 | 596,279 | D | — | — | (F2) Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-10-01 | M | D | 1,500 | $0.00 | 126,135 | D | $1.68 · — to 2029-03-13 | 1,500 Common Stock | (F8) The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |